ABSTRACT The administration of adriamycin to rates increased (P < 0.01) the interval, measured in msec, of the electrocardiographic QRS traces in rats, and the magnitude of the increase was ca. 50%. The administration of coenzyme Qio to such adriamycin-treated rats allowed "rescue" or restoration of a normal QRS complex after 7 days of administration of coenzyme Qio. The QRS complex then remained normalized during the subsequent period of 21-30 days, by which time the cumulative dose of adriamycin had reached 24 mg/kg. Also, the QRS interval was lower (P < 0.01) on day 33 than it was for rats treated to the same day with adriamycin alone. Coenzyme Q1o offers promise of rescue from at least some of the cardiotoxicity occurring in adriamycin-treated cancer patients, probably by a similar mechanism to that of the clinical rescue from toxicity of methotrexate by a cofactor of folic acid (citrovorum factor).
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The cardiotoxicity of adriamycin to cancer patients has become a widely recognized side effect and has resulted in a recommended maximum dosage of 550 mg/M2 body surface. This cardiotoxicity has also been observed at dosage levels lower than 550 mg/M2, and a consideration to exceed this maximum dosage has necessitated decisions on comparing the risk of tumor growth with the risk of congestive heart failure that results from the side effect. The clinical importance of adriamycin for cancer therapy has led to ongoing and diversified broad investigations toward the elucidation of the mechanism of the cardiotoxicity and its possible control.
Noting (8) summarized the adriamycin-induced cardiomyopathy and congestive heart failure in rats, and included histological data on myocardial changes and ultrastructural alterations. Lenaz and Page (9) reviewed the pathogenesis of the cardiomyopathy due to adriamycin and the clinical status of the cardiotoxicity.
Combs et al. (10) found that treatment of mice with CoQiO before adriamycin administration allowed an increase (P < 0.05) in survival from 36% to 80% and from 42% to 86%, respectively, in two protocols. The sequential data of Zbinden et al. (11, 12) indicated protection by CoQ against the electrocardiographic changes in rats subjected to the cardiotoxicity of adriamycin, but these workers considered their findings only preliminary. Choe et al. (13) definitively demonstrated that the widening of the electrocardiographic QRS interval did not appear when CoQ1o had been administered to adriamycintreated rats.
The clinical practice of "rescue" by the citrovorum factor (a coenzyme) from the toxicity of deliberately chosen high dosages of methotrexate (an enzyme inhibitor) for cancer patients is widely known. It was considered important to test for the rescue by CoQ1o from at least some of the cardiotoxicity of adriamycin in rats, as judged by electrocardiographic parameters. The conduct and results of these rescue experiments are described herein.
MATERIALS AND METHODS
Male Sprague-Dawley rats from the Tempco Breeding Laboratories, Houston, TX, were fed Wayne Lab Blox and water ad lib. The rats were maintained on 12-hour light-dark cycles.
They weighed approximately 180-200 g when the protocol was started.
A Physiograph desk model 4A with solid-state electronics from Narco Biosystems, Houston, TX, was used to obtain the electrocardiograph recordings. Needle electrodes were inserted under the skin without anesthesia for the limb lead at position 2. The speed of the paper was 10 cm/sec. Averages The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. Those rats receiving adriamycin and showing a widening of the QRS complex were divided into two groups, so that there were no significant differences between the mean values of the two groups in terms of the QRS complex or the body weight.
One of these groups was treated with both CoQ10 and adriamycin, and the second group was continued on the treatment with adriamycin alone.
For a statistical analysis, differences of mean values were determined by the analysis of variances followed by Scheffe's method of multiple contrast (14) .
RESULTS AND DISCUSSION
This study was conducted in five protocols, and the data that demonstrate the rescue by CoQi0 from the toxicity of adriamycin are summarized in Tables 1 through 4 as the toxicity was monitored by the QRS complex.
The 21 selected rats before any treatment had a mean value of the QRS complex of 15.5 ± 0.5 msec.
The data in Table 1 show that 4 of these 21 rats, which were then treated with water as the vehicle for adriamycin for a period of 33 days, during which time the QRS complex was monitored six times, gave a mean value of 15.9 + 0.3 msec. Similarly, 4 other rats from the initial group of 21 were treated with Tween-20 over a period of 33 days, and, after similar monitoring of the QRS complex, a mean value of 17.0 i 0.4 msec was obtained.
There is no significant difference between the mean values of the QRS complex for the initial group and for the two subsequent subgroups that were treated with the two vehicles.
The data in Table 2 for the remaining 13 of the 21 rats, which were treated with adriamycin alone at a dosage level of 1 mg/kg per day for 5 days a week for a total of 12 injections, or 12 mg/kg as a cumulative dose. On day 0 of this protocol, before the first dose of adriamycin, the mean value for the QRS complex was 14.9 + 0.6 msec. On day 14, after a cumulative dose of 12 mg, the mean value of the QRS was 22.2 + 0.7 msec, which is significantly higher (P < 0.01). In this manner, the toxicity of adriamycin could be monitored by the QRS complex as a criterion, and the toxicity was clearly evident.
In our previous study by Choe et al. (13) , CoQi0 prevented Mean 22.3 ± 0.5 Six of the 13 rats described in Table 2 were treated as shown.
the widening of the QRS complex and the elongation of the Q-T interval in adriamycin-treated rats.
The 13 rats of Table 2 were then divided into two groups of 6 and 7 rats each, and they were treated according to the data in Tables 3 and 4 .
In Table 3 , the data are shown for the group of 6 rats continued on the treatment of adriamycin alone during days 14-33, during which period the cumulative dose of adriamycin increased from 12 to 27 mg/kg. The QRS complex remained as an unchanged and widened interval with a mean value of 22.3 ± 0.5 msec.
The data in Table 4 are on the group of 7 rats that were treated both with adriamycin and CoQio. These data show the rescue or the restoration of a normal QRS interval after 7 days because the value of 17.6 ± 0.5 is not statistically different from the values for rats before treatment and the two vehicle-treated groups shown in Table 1 . The rescue is significant by P < 0.01.
It is also notable that the QRS interval remained "normalized" during the period of 21-30 days, because the mean value of 16.8 ± 0.5 msec is not different from the three control values.
It Seven of the 13 rats described in Table 2 
